Tesamorelin 8mg + Ipamorelin 8mg

Tesamorelin + Ipamorelin is a dual-peptide research blend combining two peptides that act on growth hormone release through different receptor pathways: Tesamorelin, a GHRH (growth hormone-releasing hormone) analog, and Ipamorelin, a selective GH secretagogue that acts on the ghrelin receptor. Unlike single-compound research products such as AOD-9604 or 5-Amino-1MQ, this blend is studied both for each peptide’s individual activity and for their combined effect on the GH release pathway.

Why These Two Are Studied Together

Tesamorelin and Ipamorelin act on different receptors involved in growth hormone regulation:

• Tesamorelin binds the GHRH receptor, mimicking the body’s natural signal to release growth hormone from the pituitary.
• Ipamorelin binds the ghrelin receptor, triggering GH release through a separate signaling pathway while showing selectivity that limits effects on cortisol and prolactin in research models.

Researchers combine the two to study whether stimulating both pathways together produces a different GH release pattern than either compound alone — a common structure–function question in peptide research.

Research Focus

Studies involving this combination generally examine:

• Growth hormone secretion pathways
• GHRH-receptor activity
• Ghrelin-receptor (GH secretagogue) activity
• Comparative and combined pharmacodynamics of GHRH analogs and GH secretagogues
• Pituitary signaling research models

Findings come from in vitro and animal research models. They describe mechanisms observed under experimental conditions and do not establish outcomes in humans.

Mechanism of Action

Tesamorelin stimulates the pituitary gland by binding the GHRH receptor, the same receptor targeted by the body’s natural GHRH signal. Ipamorelin acts through a separate pathway, binding the ghrelin receptor to stimulate GH release while showing a research profile more selective than earlier-generation GH secretagogues. Studying the two together allows researchers to examine whether dual-pathway stimulation alters the timing, magnitude, or pattern of GH release compared to single-pathway stimulation.

Specifications

For laboratory research use only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease.